Radioligand Therapy Continues to Show Promise for Metastatic CRPC
Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225Ac-PSMA) had a “substantial antitumor effect” in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC), a large, retrospective, multicenter study showed. Data on 488 men showed an overall survival (OS) of 15.5 months and median progression-free survival (PFS) of 7.9 months. A third of the patients had […]
FDA Approves First Targeted Radioligand Therapy for Metastatic Prostate Cancer
On Wednesday, the FDA approved the first targeted therapeutic radioligand for progressive, metastatic castration-resistant prostate cancer (mCRPC) with prostate-specific membrane antigen (PSMA) expression. Consisting of a targeting compound and a therapeutic radioisotope, lutetium Lu 177 vipivotide tetraxetan (Pluvicto) hones in on PSMA-expressing mCRPC, as identified by a companion diagnostic test (gallium Ga 68 Gozetotide injection, […]